

## Annual General Meeting of BioGaia

The Annual General Meeting of BioGaia AB (publ) on 6 May 2022 voted, among other things, to approve the following resolutions:

- adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet
- discharge from liability for the Board members and the CEO
- a dividend of SEK 3.63 per share plus an extra dividend of SEK 11.29 per share resulting in a total dividend of SEK 14.92 per share and a grant of SEK 2.9 million to “The Foundation to Prevent Antibiotic Resistance” that was founded by BioGaia in 2017. The purpose of the foundation is to reduce antibiotic resistance through support to research, education and information activities that promote of the use of products and methods that prevent and therefore reduce the use of antibiotics and the risk of antibiotic resistance
- a share split of the company's shares, whereupon each share, regardless of series, is divided into five new shares, increasing the number of shares in the company to 100,982,310, whereof 3,703,340 A shares and 97,278,970 B shares, to amend the Articles of Association to adjust the number of shares, whereby the number of shares may amount to not less than 100,000,000 and not more than 400,000,000, and to authorise the Board of Directors to decide on the record date for the share split
- adoption of new remuneration guidelines for the management in accordance with the Board of Directors’ proposal
- the number of Board members shall be nine without deputies and re-election of Anthon Jahreskog, Christian Bubenheim, Ewa Björling, David Dangoor, Niklas Ringby, Peter Elving, Peter Rothschild and Vanessa Rothschild and new election of Bénédicte Flambard as Board members
- re-election of Peter Rothschild as board chairman and David Dangoor as deputy Board chairman
- the auditor shall be a registered accounting firm and re-election of the registered accounting firm Deloitte AB
- board member remuneration in an amount of SEK 685,000 to the Board chairman, SEK 475,000 to the deputy Board chairman, SEK 265,000 to each of the other Board members elected by the general meeting, SEK 110,000 to the chairman of the audit committee and SEK 55,000 each to the other members of the audit committee and SEK 45,000 to the chairman of the remuneration committee and SEK 20,000 to each to the other members of the remuneration committee
- an additional, monthly remuneration of not more than SEK 50,000 to the chairman of the Board for duties in addition to the assignment as chairman of the Board. Any such additional remuneration shall be paid according to separate agreement and the Board’s detailed decision
- auditors’ fee shall be paid according to approved account
- on a nominating committee in accordance with the nominating committee’s proposal, and
- approval of the Board of Director’s remuneration report

### Latest press releases from BioGaia

06.05.2022 Interim Management Statement January – March 2022

25.04.2022 BioGaia’s result for first quarter to exceed market expectations

05.04.2022 Notice to attend the Annual General Meeting of BioGaia AB (publ)



Press Release 6 May 2022

**For more information, please contact**

Isabelle Ducellier, CEO: +46 8 555 293 00

Alexander Kotsinas, Executive Vice President: +46 8 555 293 00

Marika Isberg, Executive Vice President: +46 8 555 293 00

**This disclosure contains information that BioGaia is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, at 12:00 CEST on 6 May 2022.**